Cellectis S.A.

ALCLS.PA

Biotechnology · Healthcare

Price

€2.87

-0.09 (-3.04%)

Market Cap

€207.6M

Exchange

Euronext Paris

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Weak

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+123.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 44.8M (2021) → 100.3M (2025)

Winston Score History

The full picture

Cellectis is a French biotechnology company that works on gene editing to create cancer treatments. Its main focus is building "off-the-shelf" CAR-T cell therapies — engineered immune cells designed to find and kill cancer cells in patients. Unlike most CAR-T treatments, which are made from a patient's own cells, Cellectis uses donor cells that can be manufactured in advance and stored, potentially making treatment faster and cheaper.

Cellectis earns revenue through research collaborations, licensing its gene-editing technology to partners, and government or institutional grants — it does not yet sell an approved commercial product. The company is headquartered in Paris, with operations in New York, and has a market cap of roughly $200 million, reflecting its early-stage status. Its core competitive asset is its proprietary TALEN gene-editing platform, but the biggest risk the company faces is burning through cash before any of its experimental therapies successfully complete clinical trials and reach regulatory approval.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-68.7% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+8.3% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$97M/ year

↑ Rising (+8% vs prior year)

128.2% of revenue

7.1x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

25.3%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~3 years

$168M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$168M cash & investments at current burn rate

Heavy R&D investment

Cellectis S.A. is putting 128% of revenue into R&D and that number is rising. That's 7.1x the sector average. With 3+ years of cash runway, they have time to let it pay off.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

55.0%

Healthy — 55.0% gross margin

Profit after running costs

Operating Margin

-449.8%

Losing money on operations — -449.8%

Return on the money invested

ROCE

-64.2%

Weak — -64.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+0.5%

Nearly flat sales (+0.5% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-77.5%

Burning cash (-77.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

1.31

Elevated debt (1.31)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial